|Bid||33.46 x 800|
|Ask||33.48 x 800|
|Day's Range||33.21 - 34.11|
|52 Week Range||29.22 - 92.17|
|Beta (3Y Monthly)||3.42|
|PE Ratio (TTM)||9.35|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.91|
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.
SAN FRANCISCO, May 23, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will also lead development of several Nektar preclinical CNS assets.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Nektar Therapeutics (NASDAQ: NKTR ) is pretty good, but it's a total spec on oncology and pain. He would rather buy Novartis AG (NYSE: ...
SAN FRANCISCO , May 15, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55 th Annual Meeting of the American Society of Clinical ...
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
Nektar Therapeutics stock popped Thursday after the company said it would present new data for a Bristol-partnered cancer treatment in June. It's near approval for a next-generation opioid.
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Nektar's Q1 financial results weren't anything to get excited about. But good things could be on the way for the biotech.
Nektar (NKTR) delivered earnings and revenue surprises of 4.23% and 10.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Francisco-based company said it had a loss of 68 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was ...
SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2019 . Cash and investments in marketable securities ...
is expected to report a quarterly loss of 69 cents a share on sales of $27.7 million after the market closes on Wednesday, based on a FactSet survey of 11 analysts. The stock has fallen 19.4% since the company last reported earnings on Feb. 28. Nektar Therapeutics is currently trading at a price-to-forward-earnings ratio of -11.7 based on the 12-month estimates of 12 analysts surveyed by FactSet.
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $4.18 billion over the last one-month into ETFs that hold NKTR are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO , May 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2019 on Wednesday, May 8, 2019 , after the close of U.S.-based financial ...
The widely followed S&P 500 marked its highest ever close, beating its previous record closing high on Sept. 20, and the Nasdaq beat its Aug. 29 all-time closing high. The S&P 500 has rallied 25% from Dec. 24, reversing a steep selloff caused by fears of higher interest rates and uncertainty around U.S. President Donald Trump's trade war with Beijing. The S&P 500 has slightly underperformed European stocks over the same time period.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NKTR. The closing price on Thursday was 22.5% off the 52-week low of $29.22 and 193% from the 52-week high of $104.88.